RecruitingNot ApplicableNCT05721677
CLABSI Prevention With Tissue Adhesive
The Impact of Central-line Exit-site Sealing With 2-octyl Cyanoacrylate Adhesive on CLABSI in Pediatric Cardiac Intensive Care Unit
Sponsor
Rabin Medical Center
Enrollment
600 participants
Start Date
Mar 15, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Our aim is to test the effect of tissue adhesive application at the Central-line exit-site on CLABSI rates in high-risk pediatric congenital heart disease patients.
Eligibility
Min Age: 0 DaysMax Age: 18 Years
Inclusion Criteria7
- All patients admitted to pediatric cardiac ICU (PCICU) defined as high-risk for CLABSI (any of):
- young age<1y \& Congenital Heart Surgery Mortality Category (STAT\\STS-EACTS) score 2-5
- Risk Adjustment for Congenital Heart Surgery (RACHS) category ≥3
- preoperative length-of-stay (LOS) >7 days
- preoperative ventilator support
- presence of a genetic abnormality
- extracorporeal membrane oxygenation (ECMO) support
Exclusion Criteria3
- Patients with on-going bacteremia
- patients with pre-existing central-line or peripherally inserted central catheter (PICC)
- parental refusal to participate.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICE2-octyl cyanoacrylate based topical skin adhesive
Tissue adhesive on CVL exit-site
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05721677
Related Trials
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
NCT0682242615 locations
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
NCT0710866019 locations